


Amalicon is dedicated to biotech projects with low development risk and substantial market potential

Amalicon roots are in rare diseases, founders were part of companies like BIOMARIN and Raptor Pharmaceuticals

Amalicon is also involved with and benefiting from highly innovative technologies like CRISPR and life science AI


Amalicon – Group has a clear structure



Amalicon develops its own projects to market

- Oranda is an oral formulation of the Bendamustine i.v. chemotherapy
 - Phase I oral Benda in preparation
 - Amalicon Team was part of the Bendamustine i.v. development
- Femoshape is a platform technology to modify Fat Cells
 - Cosmetic application, derived from AI
 - Patented product on the basis of natural ingredients
 - Potential suitable for rare disease like auto immune
- Canvivia reduces the acute symptoms of ALDH2 deficient subjects after the consumption of alcohol («Asian Flush»)
 - Canvivia is a Phase II – product with clinical Proof of Concept
- New projects
 - CRISPR, Data Mining, Peptide Drug Conjugates

Amalicon pipeline of products (2017/2018)



CellProtect small molecule CP201

- CP201 has significant advantages in the treatment of Multiple Sclerosis
 - Ability to cross the blood/brain – barrier
 - Revealed prophylactic and therapeutic effect in relevant MS models
 - Orally available
- CP201 fulfills unmet medical needs in oncology
 - CP201 is very well tolerated, also with older patients and in higher doses
 - It has shown efficacy in various tumor types, including brain
- CP201 has historic data of 1'400 mostly oncology patients
 - It can be applied alone or in combination
 - It is orally available
- CP201 will start clinical trials by Q2/2018 (tumor application)
- CP201 has various very attractive partnering options

The Corporate Governance is of high standard

- ◊ Financials & Audit
 - ◊ KBT Treuhand AG
 - ◊ Audit Treuhand AG
- ◊ Board of Directors
 - ◊ Heinz Winzeler Chairman
 - ◊ Four highly qualified new members to be elected to the Board of Directors at the extraordinary meeting of October 20, 2017
- ◊ Continuous Information Flow to Shareholders
 - ◊ Quarterly «Chairman Letter»; Semiannual Reports, Audited Annual Report, Website Access
- ◊ Shares
 - ◊ Custody by SIX Swiss Exchange; OTC trading planned by 2018

Forward – looking statements

This presentation contains statements that constitute "forward-looking statements", including – but not limited to – management's outlook for AMALICON HOLDING AG (thereafter, together with its affiliates, "AMALICON") financial performance and statements relating to the anticipated effect of transactions and strategic initiatives on the business and future development of AMALICON.

While these forward-looking statements represent AMALICON'S judgments and expectations concerning the matters described, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from AMALICON'S expectations.

AMALICON is not under any obligation to update its forward – looking statements, whether as a result of new information, future events or otherwise.

Please note that this presentation is incomplete without the additional oral comments accompanying it.

For more information; please contact info@amalicon.ch